EE05387B1 - KinasoliiniÁderivaadid,ÁnendeÁvalmistamismeetodÁjaÁkasutamine - Google Patents
KinasoliiniÁderivaadid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineInfo
- Publication number
- EE05387B1 EE05387B1 EEP200300071A EEP200300071A EE05387B1 EE 05387 B1 EE05387 B1 EE 05387B1 EE P200300071 A EEP200300071 A EE P200300071A EE P200300071 A EEP200300071 A EE P200300071A EE 05387 B1 EE05387 B1 EE 05387B1
- Authority
- EE
- Estonia
- Prior art keywords
- preparation
- quinazoline derivatives
- quinazoline
- derivatives
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00402320 | 2000-08-21 | ||
EP01401006 | 2001-04-19 | ||
PCT/GB2001/003649 WO2002016352A1 (en) | 2000-08-21 | 2001-08-15 | Quinazoline derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200300071A EE200300071A (et) | 2004-12-15 |
EE05387B1 true EE05387B1 (et) | 2011-02-15 |
Family
ID=26073540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200300071A EE05387B1 (et) | 2000-08-21 | 2001-08-15 | KinasoliiniÁderivaadid,ÁnendeÁvalmistamismeetodÁjaÁkasutamine |
Country Status (21)
Country | Link |
---|---|
US (1) | US7115615B2 (et) |
EP (1) | EP1313727A1 (et) |
JP (1) | JP2004506732A (et) |
KR (2) | KR20080027400A (et) |
CN (1) | CN100347169C (et) |
AR (1) | AR033560A1 (et) |
AU (2) | AU7860901A (et) |
BR (1) | BR0113358A (et) |
CA (1) | CA2419301C (et) |
CZ (1) | CZ2003486A3 (et) |
EE (1) | EE05387B1 (et) |
IL (2) | IL154131A0 (et) |
MX (1) | MXPA03001332A (et) |
MY (1) | MY129809A (et) |
NO (1) | NO326515B1 (et) |
NZ (1) | NZ523702A (et) |
PL (1) | PL202812B1 (et) |
RU (1) | RU2267489C2 (et) |
SK (1) | SK2142003A3 (et) |
TW (1) | TWI280960B (et) |
WO (1) | WO2002016352A1 (et) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
US6939866B2 (en) | 2000-10-13 | 2005-09-06 | Astrazeneca Ab | Quinazoline derivatives |
JP2004511479A (ja) | 2000-10-13 | 2004-04-15 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
AU2002217999A1 (en) | 2000-11-01 | 2002-05-15 | Cor Therapeutics, Inc. | Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
JP4307843B2 (ja) * | 2001-04-19 | 2009-08-05 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
US7501516B2 (en) | 2001-07-16 | 2009-03-10 | Astrazeneca Ab | Quinoline derivatives and their use as tyrosine kinase inhibitors |
GB0128109D0 (en) | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
WO2003047582A1 (en) * | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives as antitumour agents |
ATE549329T1 (de) * | 2002-02-01 | 2012-03-15 | Astrazeneca Ab | Chinazoline verbindungen |
TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
JP2005536486A (ja) * | 2002-07-09 | 2005-12-02 | アストラゼネカ アクチボラグ | 癌の処置に使用するためのキナゾリン誘導体 |
JP4703183B2 (ja) | 2002-07-15 | 2011-06-15 | シンフォニー エボルーション, インク. | 受容体型キナーゼモジュレーターおよびその使用方法 |
GB0225579D0 (en) | 2002-11-02 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
CN100354278C (zh) * | 2002-11-04 | 2007-12-12 | 阿斯利康(瑞典)有限公司 | 作为src酪氨酸激酶抑制剂的喹唑啉衍生物 |
CA2503371C (en) * | 2002-11-04 | 2011-01-11 | Astrazeneca Ab | Quinazoline derivatives as src tyrosine kinase inhibitors |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
CA2529611C (en) | 2002-12-20 | 2009-12-15 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
GB0307333D0 (en) * | 2003-03-29 | 2003-05-07 | Astrazeneca Ab | Therapeutic agent |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
AU2004275842B2 (en) | 2003-09-26 | 2010-09-02 | Exelixis Inc. | c-MET modulators and methods of use |
US7632840B2 (en) | 2004-02-03 | 2009-12-15 | Astrazeneca Ab | Quinazoline compounds for the treatment of hyperproliferative disorders |
CA2566477A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
BRPI0510963A (pt) | 2004-05-14 | 2007-11-20 | Pfizer Prod Inc | derivados pirimidina para o tratamento do crescimento anormal de células |
BRPI0510980A (pt) | 2004-05-14 | 2007-11-27 | Pfizer Prod Inc | derivados de pirimidina para o tratamento do crescimento anormal de células |
TW200626559A (en) * | 2004-10-13 | 2006-08-01 | Wyeth Corp | Anilino-pyrimidine analogs |
GB0427697D0 (en) | 2004-12-17 | 2005-01-19 | Astrazeneca Ab | Chemical process |
JP5338072B2 (ja) * | 2005-08-17 | 2013-11-13 | 宇部興産株式会社 | 4−ハロカテコール化合物の製法 |
AU2007274284B2 (en) * | 2006-07-13 | 2012-04-26 | Janssen Pharmaceutica N.V. | Mtki quinazoline derivatives |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
CA2672893C (en) | 2006-12-15 | 2016-02-23 | Abraxis Bioscience, Inc. | Triazine derivatives and their therapeutical applications |
EP2118075A1 (de) | 2007-02-06 | 2009-11-18 | Boehringer Ingelheim International GmbH | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
RS52573B (en) | 2008-02-07 | 2013-04-30 | Boehringer Ingelheim International Gmbh | SPIROCYCLIC HETEROCYCLES, THE MEDICINAL PRODUCTS CONTAINING THIS UNIT, THEIR APPLICATION AND THE PROCEDURE FOR THEIR MANUFACTURING |
NZ589883A (en) | 2008-05-13 | 2012-06-29 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline |
EP2313397B1 (de) | 2008-08-08 | 2016-04-20 | Boehringer Ingelheim International GmbH | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
US20100069340A1 (en) * | 2008-09-11 | 2010-03-18 | Wyeth | Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor |
AU2009295946B2 (en) * | 2008-09-29 | 2013-03-21 | Sirtris Pharmaceuticals, Inc. | Chromenone analogs as sirtuin modulators |
KR20210151988A (ko) | 2009-01-16 | 2021-12-14 | 엑셀리시스, 인코포레이티드 | 암의 치료를 위한 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
AU2010258964B2 (en) | 2009-06-09 | 2014-09-11 | Nantbio, Inc. | Benzyl substituted triazine derivatives and their therapeutical applications |
EP2440057A4 (en) | 2009-06-09 | 2012-12-05 | California Capital Equity Llc | TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
CN102617463A (zh) * | 2012-02-28 | 2012-08-01 | 苏州卡耐博生物技术有限公司 | 喹啉衍生物和喹唑啉衍生物及它们的制备方法 |
CN108064274A (zh) | 2014-07-30 | 2018-05-22 | 耶达研究及发展有限公司 | 用于培养多能干细胞的培养基 |
MX2020010999A (es) | 2018-04-18 | 2021-01-20 | Constellation Pharmaceuticals Inc | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. |
CN112262143A (zh) | 2018-05-21 | 2021-01-22 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
EP3914698A1 (en) | 2019-01-23 | 2021-12-01 | Yeda Research and Development Co. Ltd | Culture media for pluripotent stem cells |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411963A (en) | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
WO1992020642A1 (en) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
EP0746554A1 (en) | 1994-02-23 | 1996-12-11 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
AU2096895A (en) * | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (et) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
EP2295415A1 (en) | 1995-03-30 | 2011-03-16 | OSI Pharmaceuticals, Inc. | Quinazoline derivatives |
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
CZ291386B6 (cs) | 1996-02-13 | 2003-02-12 | Zeneca Limited | Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
WO1998002434A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
AUPO257096A0 (en) * | 1996-09-25 | 1996-10-17 | Bhp Steel (Jla) Pty Limited | Production of striped coatings on strip |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
WO1999061428A1 (en) | 1998-05-28 | 1999-12-02 | Parker Hughes Institute | Quinazolines for treating brain tumor |
JP2004504259A (ja) | 1998-06-30 | 2004-02-12 | パーカー ヒューズ インスティテュート | Jak−3インヒビターを用いたc−jun発現の阻害方法 |
ATE292121T1 (de) | 1998-08-21 | 2005-04-15 | Parker Hughes Inst | Chinazolinderivate |
DK1119567T3 (da) | 1998-10-08 | 2005-07-25 | Astrazeneca Ab | Quinazolinderivater |
IL132366A0 (en) * | 1998-10-15 | 2001-03-19 | Cell Pathways Inc | Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds |
US7074800B1 (en) * | 1999-02-10 | 2006-07-11 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors |
BR0008524A (pt) | 1999-02-27 | 2001-12-18 | Boehringer Ingelheim Pharma | Heterociclos bicìclicos, composiçõesfarmacêuticas que contêm esses compostos, seuuso e processos para a sua prerapação |
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
GB9922173D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
SK3832002A3 (en) | 1999-09-21 | 2002-11-06 | Astrazeneca Ab | Quinazoline compounds and pharmaceutical compositions containing them |
CZ20021009A3 (cs) | 1999-09-21 | 2002-06-12 | Astrazeneca Ab | Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv |
AU779695B2 (en) | 2000-04-07 | 2005-02-10 | Astrazeneca Ab | Quinazoline compounds |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
JP2004511479A (ja) | 2000-10-13 | 2004-04-15 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
US6939866B2 (en) | 2000-10-13 | 2005-09-06 | Astrazeneca Ab | Quinazoline derivatives |
WO2002034744A1 (en) | 2000-10-25 | 2002-05-02 | Astrazeneca Ab | Quinazoline derivatives |
JP4307843B2 (ja) | 2001-04-19 | 2009-08-05 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
US7501516B2 (en) | 2001-07-16 | 2009-03-10 | Astrazeneca Ab | Quinoline derivatives and their use as tyrosine kinase inhibitors |
-
2001
- 2001-08-15 CN CNB018177409A patent/CN100347169C/zh not_active Expired - Fee Related
- 2001-08-15 KR KR1020087005460A patent/KR20080027400A/ko not_active Application Discontinuation
- 2001-08-15 KR KR1020037002441A patent/KR100821446B1/ko not_active IP Right Cessation
- 2001-08-15 NZ NZ523702A patent/NZ523702A/en unknown
- 2001-08-15 AU AU7860901A patent/AU7860901A/xx active Pending
- 2001-08-15 SK SK214-2003A patent/SK2142003A3/sk not_active Application Discontinuation
- 2001-08-15 CA CA002419301A patent/CA2419301C/en not_active Expired - Fee Related
- 2001-08-15 IL IL15413101A patent/IL154131A0/xx unknown
- 2001-08-15 MX MXPA03001332A patent/MXPA03001332A/es active IP Right Grant
- 2001-08-15 AU AU2001278609A patent/AU2001278609B2/en not_active Ceased
- 2001-08-15 US US10/344,678 patent/US7115615B2/en not_active Expired - Fee Related
- 2001-08-15 WO PCT/GB2001/003649 patent/WO2002016352A1/en active IP Right Grant
- 2001-08-15 BR BR0113358-6A patent/BR0113358A/pt not_active Application Discontinuation
- 2001-08-15 EP EP01956688A patent/EP1313727A1/en not_active Withdrawn
- 2001-08-15 PL PL360591A patent/PL202812B1/pl not_active IP Right Cessation
- 2001-08-15 EE EEP200300071A patent/EE05387B1/et not_active IP Right Cessation
- 2001-08-15 CZ CZ2003486A patent/CZ2003486A3/cs unknown
- 2001-08-15 RU RU2003107683/04A patent/RU2267489C2/ru not_active IP Right Cessation
- 2001-08-15 JP JP2002521453A patent/JP2004506732A/ja not_active Ceased
- 2001-08-20 MY MYPI20013907A patent/MY129809A/en unknown
- 2001-08-21 AR ARP010103972A patent/AR033560A1/es not_active Application Discontinuation
- 2001-09-14 TW TW90122895A patent/TWI280960B/zh not_active IP Right Cessation
-
2003
- 2003-01-26 IL IL154131A patent/IL154131A/en not_active IP Right Cessation
- 2003-02-20 NO NO20030795A patent/NO326515B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2001278609B2 (en) | 2005-04-14 |
MY129809A (en) | 2007-05-31 |
AR033560A1 (es) | 2003-12-26 |
RU2267489C2 (ru) | 2006-01-10 |
US7115615B2 (en) | 2006-10-03 |
PL360591A1 (en) | 2004-09-06 |
CA2419301A1 (en) | 2002-02-28 |
EE200300071A (et) | 2004-12-15 |
CN1471527A (zh) | 2004-01-28 |
BR0113358A (pt) | 2003-07-01 |
TWI280960B (en) | 2007-05-11 |
CA2419301C (en) | 2009-12-08 |
JP2004506732A (ja) | 2004-03-04 |
IL154131A0 (en) | 2003-07-31 |
US20040034046A1 (en) | 2004-02-19 |
SK2142003A3 (en) | 2003-07-01 |
NO20030795D0 (no) | 2003-02-20 |
MXPA03001332A (es) | 2004-07-08 |
KR20030022416A (ko) | 2003-03-15 |
KR100821446B1 (ko) | 2008-04-10 |
AU7860901A (en) | 2002-03-04 |
CN100347169C (zh) | 2007-11-07 |
PL202812B1 (pl) | 2009-07-31 |
KR20080027400A (ko) | 2008-03-26 |
NO326515B1 (no) | 2008-12-22 |
NZ523702A (en) | 2004-08-27 |
NO20030795L (no) | 2003-04-04 |
IL154131A (en) | 2010-04-15 |
WO2002016352A1 (en) | 2002-02-28 |
CZ2003486A3 (cs) | 2003-05-14 |
EP1313727A1 (en) | 2003-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE05387B1 (et) | KinasoliiniÁderivaadid,ÁnendeÁvalmistamismeetodÁjaÁkasutamine | |
EE200200118A (et) | Terapeutilised kinasoliini derivaadid, nende valmistamise meetod ning kasutamine | |
EE200200715A (et) | Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena | |
EE200300544A (et) | 4-anilinokinoliin-3-karboksamiidid, nende kasutamine ning valmistamine | |
CY2013011I2 (el) | Μεθοδος χορηγησης διφωσφονικων | |
EE200300207A (et) | Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon | |
NO20032726D0 (no) | Kinazolinderivater, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for fremstilling derav | |
HUP0300527A3 (en) | Pyrrolopyrimidinone derivatives, process of preparation and use | |
MXPA03006260A (es) | Derivados de amina sustituidos y metodos de uso. | |
NO20012567D0 (no) | Azepinoindolderivater, fremstilling og anvendelse derav | |
EE200300048A (et) | Bensimidasooli derivaadid, nende valmistamine ja terapeutiline kasutamine | |
ID30590A (id) | Celana sekali pakai jenis-celana pendek | |
NO20021379D0 (no) | Benzodiazepin-derivater, fremstilling og anvendelse derav | |
NO20041272L (no) | Tetracycline derivatives and methods of use thereof | |
NO20032332D0 (no) | Benzodiazepinderivatforbindelser, fremgangsmåte til fremstilling og anvendelse derav | |
NO20031838D0 (no) | Benzokazinonderivater, deres fremstilling og anvendelse | |
DK1334106T3 (da) | Imidazolderivater, fremstillingsmetoder deraf og anvendelse deraf | |
FI20000818A0 (fi) | Dermatologinen käyttö ja valmiste | |
DK1043307T3 (da) | 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse | |
DE60144456D1 (de) | DibenzoÄb,fÜazepin-Derivate und ihre Herstellung | |
IS2331B (is) | 2-arýlimínó-2,3-díhýdróþíasólafleiður, aðferðir til að framleiða þær og meðferðarfræðileg notkun þeirra | |
DE60117096D1 (de) | Dihydroindol- und tetrahydrochinolinderivate | |
NO20024107L (no) | Tienopyridin derivater, deres fremstilling og anvendelse | |
FI19992142A (fi) | Vesineulattu kuitukangas, menetelmä sen valmistamiseksi ja sen käyttö | |
ATE299873T1 (de) | Substituierte c-furan-2-yl-methylamin- und c- thiophen-2-yl-methylamin-derivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapsed by not paying the annual fees |
Effective date: 20110815 |